| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BIX-01294 | CTRPv2 | pan-cancer | AAC | -0.0068 | 0.8 |
| mRNA | AZD4547 | CTRPv2 | pan-cancer | AAC | 0.0075 | 0.8 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.0093 | 0.8 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0068 | 0.8 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | 0.0074 | 0.8 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.0064 | 0.8 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | -0.0064 | 0.8 |
| mRNA | tigecycline | CTRPv2 | pan-cancer | AAC | 0.0095 | 0.9 |
| mRNA | SB-743921 | CTRPv2 | pan-cancer | AAC | 0.0062 | 0.9 |